In Brief: Qmed
This article was originally published in The Gray Sheet
Executive Summary
Qmed: Appoints Howard Waltham as chairman of the board, replacing company founder Michael Cox, who will continue as Qmed president and CEO. From 1985 to 1995, Waltham served as chairman and CEO of Sanus Corp. Health System, a national HMO company. In early May, Qmed finalized a strategic alliance with SmithKline Beecham under which SKB obtained exclusive rights to market and sell Qmed's ohms/cad (on-line health management system for coronary artery disease) to U.S. managed care companies in return for an equity investment -- 177,777 shares of Qmed common stock at $11.25 per share -- from SKB's venture capital affiliate S.R. One, Ltd. S.R. One also obtained a warrant to acquire an additional 63,492 shares of Qmed common at $15.75 per share...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.